{"id":"W2756647112","doi":"10.1158/1535-7163.mct-17-0456","title":"Targeting the MAPK Signaling Pathway in Cancer: Promising Preclinical Activity with the Novel Selective ERK1/2 Inhibitor BVD-523 (Ulixertinib)","year":2017,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":234,"is_retracted":false,"has_abstract":true,"ca_institutions":"Phenomenome Discoveries (Canada)","funders":"","keywords":"MAPK/ERK pathway; Medicine; In vivo; Melanoma; Cancer research; Cancer; Pharmacology; Phosphorylation; Potency; MEK inhibitor; Targeted therapy; In vitro; Internal medicine; Biology; Cell biology; Biochemistry","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005983174,0.0003350946,0.0002804821,0.00002667272,0.0006913702,0.0001749053,0.0007290062,0.0002290962,0.00001004727],"category_scores_gemma":[0.00006628419,0.0002038801,0.0001312498,0.0001109119,0.0002948581,0.00001594359,0.0002242417,0.0005167582,0.000001683382],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00007914755,"about_ca_system_score_gemma":0.0004856873,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004249576,"about_ca_topic_score_gemma":0.000813902,"domain_scores_codex":[0.9980711,0.0001957709,0.0002758938,0.0006116888,0.0003113881,0.0005341897],"domain_scores_gemma":[0.9984624,0.00005429765,0.000393018,0.0008553367,0.0001618544,0.00007310725],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.0004083852,0.00010762,0.00444972,0.00002244973,0.0002305583,0.00001111606,0.00044132,0.0010566,0.982826,0.00004002536,0.00005906405,0.01034715],"study_design_scores_gemma":[0.00122398,0.0002889523,0.003783432,0.00009224686,0.00007850915,0.000007154632,0.00012631,0.0006650849,0.9742095,0.00003835936,0.01911891,0.0003675025],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9881299,0.002235091,0.005285225,0.002857035,0.0003002044,0.0007680457,0.0000460005,0.0000191284,0.000359434],"genre_scores_gemma":[0.9971607,0.0001898927,0.0003062163,0.001269556,0.0005307146,0.0003141504,0.00001176661,0.0000701098,0.0001469397],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01905984,"threshold_uncertainty_score":0.8313987,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03944351150700175,"score_gpt":0.3106321426094479,"score_spread":0.2711886311024461,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}